Clinical and laboratory characteristics of patients with newly diagnosed Hodgkin disease
| Characteristic . | IL-13 positive . | IL-13 negative . | ||
|---|---|---|---|---|
| N . | % . | N . | % . | |
| Number of patients | 11 | 97 | ||
| Age (years) | ||||
| median | 31.4 | 35.9 | ||
| range | 16-63 | 16-70 | ||
| Sex | ||||
| female | 6 | 54.5 | 35 | 36.1 |
| male | 5 | 45.5 | 62 | 63.9 |
| Histology | ||||
| nodular sclerosis | 8 | 72.7 | 68 | 70.1 |
| mixed cellularity | 1 | 9 | 15 | 15.4 |
| lymphocyte predominance | 2 | 18.1 | 10 | 9.1 |
| unclassified | 1 | 11.1 | 4 | 4.1 |
| Ann Arbor Stage | ||||
| I | 0 | 0 | 11 | 11.3 |
| II | 7 | 63.6 | 52 | 53.6 |
| III | 4 | 36.3 | 20 | 20.6 |
| IV | 1 | 9 | 14 | 14.4 |
| B symptoms | ||||
| no | 6 | 55.6 | 71 | 73.1 |
| yes | 5 | 45.4 | 26 | 26.8 |
| Extranodal involvement | 1 | 9 | 4 | 4.1 |
| Characteristic . | IL-13 positive . | IL-13 negative . | ||
|---|---|---|---|---|
| N . | % . | N . | % . | |
| Number of patients | 11 | 97 | ||
| Age (years) | ||||
| median | 31.4 | 35.9 | ||
| range | 16-63 | 16-70 | ||
| Sex | ||||
| female | 6 | 54.5 | 35 | 36.1 |
| male | 5 | 45.5 | 62 | 63.9 |
| Histology | ||||
| nodular sclerosis | 8 | 72.7 | 68 | 70.1 |
| mixed cellularity | 1 | 9 | 15 | 15.4 |
| lymphocyte predominance | 2 | 18.1 | 10 | 9.1 |
| unclassified | 1 | 11.1 | 4 | 4.1 |
| Ann Arbor Stage | ||||
| I | 0 | 0 | 11 | 11.3 |
| II | 7 | 63.6 | 52 | 53.6 |
| III | 4 | 36.3 | 20 | 20.6 |
| IV | 1 | 9 | 14 | 14.4 |
| B symptoms | ||||
| no | 6 | 55.6 | 71 | 73.1 |
| yes | 5 | 45.4 | 26 | 26.8 |
| Extranodal involvement | 1 | 9 | 4 | 4.1 |